Completion axillary lymph node dissection for the identification of pN2–3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial-Reference-Cited by-同舟云学术

Completion axillary lymph node dissection for the identification of pN2–3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial

Published:2024-09 Issue:9 Volume:25 Page:1222-1230
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

de Boniface Jana,Appelgren Matilda,Szulkin Robert,Alkner Sara,Andersson Yvette,Bergkvist Leif,Frisell Jan,Gentilini Oreste Davide,Kontos Michalis,Kühn Thorsten,Lundstedt Dan,Offersen Birgitte Vrou,Olofsson Bagge Roger,Reimer Toralf,Sund Malin,Christiansen Peer,Rydén Lisa,Filtenborg Tvedskov Tove

Publisher

Elsevier BV

Reference25 articles.

1. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981-22023 AMAROS trial;Bartels;J Clin Oncol,2023

2. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial;Giuliano;JAMA,2017

3. Eight-year follow up result of the OTOASOR trial: the optimal treatment of the axilla - surgery or radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: a randomized, single centre, phase III, non-inferiority trial;Sávolt;Eur J Surg Oncol,2017

4. Preservation of axillary lymph nodes compared with complete dissection in T1-2 breast cancer patients presenting one or two metastatic sentinel lymph nodes: the SINODAR-ONE multicenter randomized clinical trial;Tinterri;Ann Surg Oncol,2022

5. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial;Donker;Lancet Oncol,2014

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Abemaciclib Therapy Using the MonarchE Criteria Results in Large Numbers of Excess Axillary Node Clearances—Time to Pause and Reflect?;Cancers;2024-09-04

2. Time to abandon axillary lymph node dissection in early-stage breast cancer;The Lancet Oncology;2024-09